FDA Approves Pediatric Risankizumab - Quiz - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA Approves Pediatric Risankizumab

Approval expands risankizumab use to pediatric plaque psoriasis and psoriatic arthritis and includes a new 55-mg prefilled syringe for weight-based dosing in patients weighing less than 40 kg.

  • By

  • Kathryn Wighton

  • June 29, 2026

  • 3 min

Share

Original Source(s)

FDA Approves Pediatric Risankizumab

  • by Kathryn Wighton

  • June 29, 2026

Related Content

Contact Lenses as Optical Interventions for Myopia Management

The latest in our myopia series from The European Myopia Network

Do antihistamines help atopic dermatitis?

First-generation H1 antihistamines likely increase cognitive impairment, with cognitive effects differing among second-generation antihistamines.

Educators weigh how to use AI without losing critical thinking

Greater productivity is not necessarily indicative of greater knowledge.